Recent news on Periostat

CollaGenex Pharmaceuticals to Present at the Friedman, Billings ...  -  May 24, 2007
Genetic Engineering News (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) is a trademark of CollaGenex Pharmaceuticals, Inc.

CollaGenex Pharmaceuticals to Host First Quarter 2007 Financial ...  -  26 Apr 2007
PharmaLive.com (press release),Periostat(R), Restoraderm(R) and Oracea(R) are registered trademarks and IMPACS(TM) is a trademark of CollaGenex Pharmaceuticals, Inc.

CollaGenex Pharmaceuticals Provides Update on Examination of ...  -  Apr 23, 2007
PharmaLive.com (press release),Periostat(R) and Restoraderm(R) are registered trademarks and IMPACS(TM), and Oracea(R) are trademarks of CollaGenex Pharmaceuticals, Inc.

Answering Questions On Lamps, Spices And Antioxidants  -  Apr 3, 2007
Evening Bulletin,Answer: The answer of the Council on Scientific Affairs is that Periostat can help stop the progression of periodonitis when used as directed as an adjunct

Ugly fallout of gum disease  -  Apr 1, 2007
Fort Wayne Journal Gazette,Periostat, a medication developed at Stony Brook’s Dental School, also has proved useful in inhibiting enzymes that break down the collagen and cause bone

CollaGenex Pharmaceuticals (CGPI) Tops Q4 EPS by 14, Issues FY07 ...  -  Mar 6, 2007
StreetInsider.com (subscription),For 2007, total revenues are expected to be: Revenues from Oracea, Periostat, Pandel, the Atrix products, contract revenues from the Primus products and

CollaGenex Pharmaceuticals Reports Financial Results for the ...  -  Mar 6, 2007
Genetic Engineering News (press release),Total revenues: Revenues from Oracea, Periostat(R), Pandel(R), the Atrix products, contract revenues from the Primus products and grant revenue from the

At the root of the problem:  -  Mar 18, 2007
Evansville Courier & Press (subscription),Periostat, a medication developed at Stony Brook's Dental School, also has proved useful in inhibiting enzymes that break down the collagen and cause bone

CollaGenex Pharmaceuticals to Present at the Cowen and Company ...  -  Mar 7, 2007
PharmaLive.com (press release),Periostat(R) and Restoraderm(R) are registered trademarks and IMPACS(TM), SansRosa(TM) and Oracea(TM) are trademarks of CollaGenex Pharmaceuticals, Inc.

Gum bug sandwich  -  Feb 28, 2007
RDH,The periodontist had diagnosed him with aggressive periodontitis, and he was taking Periostat bid as directed. I questioned him about his home care and he

Stony Brook ranks high  -  Feb 22, 2007
Long Island Business News (subscription),Other inventions included Periostat, a drug used to fight gum disease. Stony Brook finished slightly behind the University of Michigan, which had $16.7

CollaGenex Pharmaceuticals Signs License and Supply Agreement with ...  -  Dec 21, 2006
PipelineReview.com (press release),CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes

MediGene's Acquisition of a License on Oracea Gives the Signal for ...  -  Dec 20, 2006
PharmaLive.com (press release),Periostat® and Restoraderm® are registered trademarks and IMPACS™, SansRosa™ and Oracea™ are trademarks of CollaGenex Pharmaceuticals, Inc. Novacort™ and

CollaGenex Pharmaceuticals to Present at the RBC Capital Markets ...  -  Dec 6, 2006
American Digital Networks (press release),CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes

MediGene's Acquisition of a License on Oracea Gives the Signal for ...  -  Dec 20, 2006
PharmaLive.com (press release),Periostat® and Restoraderm® are registered trademarks and IMPACS™, SansRosa™ and Oracea™ are trademarks of CollaGenex Pharmaceuticals, Inc. Novacort™ and

CollaGenex Pharmaceuticals Reports Financial Results for the Third ...  Nov 8, 2006
Net revenues from Periostat(R), Pandel(R), the Atrix products, contract revenues from the Primus products and grant revenue from the previously announced NIH ... -Business Wire (press release), Business news in brief  Nov 4, 2006
Oracea is a formulation of doxycycline, the same active ingredient in CollaGenex's gum-disease treatment Periostat. The company, a ... -Philadelphia Inquirer, CollaGenex Pharmaceuticals Announces USPTO Allowance of Oracea ...  Nov 3, 2006
CollaGenex additionally currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the ... -Business Wire (press release), CollaGenex Pharmaceuticals to Present at the UBS Global Life ...  Sep 19, 2006
CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes ... -Business Wire

CollaGenex Pharmaceuticals to Present at the RBC Capital Markets ...  -  Dec 6, 2006
American Digital Networks (press release),CollaGenex also currently sells Periostat(R), which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes

CollaGenex Pharmaceuticals Reports Financial Results for the ...  Aug 2, 2006
...were $3.8 million in the second quarter of 2006 compared to $6.9 million in the second quarter of 2005, reflecting reduced sales of Periostat(R) following the ... -Business Wire

2nd quarter good at 3 local biotechs  Aug 3, 2006
Stewart said revenues fell after CollaGenex’s signature dental drug, Periostat, lost its patent protection and became available as a generic. ... -phillyBurbs.com

Business news in brief  Aug 3, 2006
...reported sharply lower second-quarter revenue based on reduced sales of its dental treatment Periostat after lower-cost generic versions hit the market in May ... -Philadelphia Inquirer

Collagenex responds to patent situation  Jul 21, 2006
Oracea contains doxycycline, the same active ingredient as CollaGenex's gum disease treatment Periostat. The company began focusing ... -Philadelphia Business Journal



CollaGenex Pharmaceuticals Reports Financial Results For the First ...  May 3, 2006
...$3.7 million compared to approximately $12.0 million in the first quarter of 2005, reflecting significantly reduced sales of Periostat(R) following the ... - Genetic Engineering News

CollaGenex Posts Wider 1Q Loss  May 3, 2006
...said Wednesday that its first-quarter loss widened significantly as generic sales cut heavily into its Periostat gum disease treatment sales. ... - Houston Chronicle

CollaGenex Pharma Q1 Loss Widens On Lower Sales Due To Generic ...  May 3, 2006
...on Wednesday reported first quarter results, posting a net loss that widened from last year on decrease in sales of the company's Periostat drug due to the ... - Trading Markets

CollaGenex Pharmaceuticals Net Loss Widens In Q1 - Quick Facts  May 3, 2006
...totaled $3.7 million compared to $12 million in the prior year quarter, with the company attributing the decline in revenues to the reduced sales of Periostat. ... - Trading Markets

CollaGenex Pharmaceuticals to Host First Quarter 2006 Earnings ...  Apr 26, 2006
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News

Biotechs have high hopes for ’06  May 4, 2006
The loss reflects reduced sales of the company’s Periostat dental drug since generic competition entered the market a year ago, said CEO Colin Stewart. ... - phillyBurbs.com





CollaGenex Pharmaceuticals to Present at the SunTrust 35th Annual ...  Apr 4, 2006
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News

Pharma? Think small  Mar 10, 2006
...dental remedies. But in 2002 a study found that its drug for severe gum disease, Periostat, could also clear up acne. The Collagenex ... - CNNMoney.com



CollaGenex Pharmaceuticals to Present at the SG Cowen 26th Annual ...  Mar 1, 2006
CollaGenex also currently sells Periostat, which the Company developed as the first pharmaceutical to treat periodontal disease by inhibiting the enzymes that ... - Genetic Engineering News,

CollaGenex seeks UK approval for Oracea  Feb 28, 2006
This loss was driven by significantly reduced sales of Periostat following the introduction of generic competition in May 2005. ... - Pharmaceutical Business Review

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional